1 / 42

‘Cures For A Broken Heart’

‘Cures For A Broken Heart’. Cardiogenic Shock, IABP, Vasopressors, Inotropes & Cardiologists Daniel Orr. The Problem. Definition ‘Decreased cardiac output and evidence of tissue hypoxia in the presence of adequate intravascular volume.’ Clinically

ernie
Download Presentation

‘Cures For A Broken Heart’

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ‘Cures For A Broken Heart’ • Cardiogenic Shock, IABP, Vasopressors, Inotropes & Cardiologists Daniel Orr

  2. The Problem • Definition • ‘Decreased cardiac output and evidence of tissue hypoxia in the presence of adequate intravascular volume.’ • Clinically • Cool, mottled extremities, poor capillary return • Clouded sensorium • Hypotension • Oliguria • Pulmonary ‘Congestion’ • Exclusion of other causes

  3. The Problem • Definition • Haemodynamic criteria • SBP <90mmHg >30min • CI <2.2L/min m2 • PCWP >15mmHg Hollenberg, SM. Kavinsky, CJ. Ann Intern Med. 1999;131:47-59

  4. The Problem • Incidence • Range 5 – 10% patients presenting with AMI • Does not account for out of hospital arrests/death

  5. The Trigger • Cause & Epidemiology • Myocardial Infarct • Majority of cases – Pump failure • Include right ventricular infarct • Mechanical Events • Acute MR • Rupture IVS or free wall • Myocardial Dysfunction • Myocarditis, Cardiomyopathy, Septic Shock, Prolonged CPB

  6. Risk Factors & Evolution • Shock • More likely in those with anterior and previous infarct, old, the diabetic, PVD, CVA • Time Course • Of those reaching hospital minority of patients in shock ~ 10% • 7 hours typical delay between infarct and symptomatic shock

  7. The Breakdown • Pathophysiology • Described as a downward spiral of events of compounding events • Key Elements • Primary Pump Failure • Sympathetic Nervous System Activation

  8. The Breakdown • Pathophysiology • Pump Failure • Both systolic & diastolic components • Systolic • Reduction in stroke volume, therefore cardiac output • Remainder of myocardium hypercontractile, increasing O2 consumption • Significant dependence on coronary flow, potentially already compromised by disease • All worsen ischaemia

  9. The Breakdown • Pathophysiology • Pump Failure • Diastolic • Perfusion reduced by hypotension and SNS induced tachycardia • Increased EDP additionally reduces perfusion • Increased wall stress increases O2 consumption • All worsen ischaemia

  10. The Fallout • Pathophysiology • Sympathetic Activation • Attempt to maintain organ perfusion • Results • Tachycardia • Increased circulating catecholamines • Activation of RAA system • Consequences • Increased myocardial O2 demand via HR, contractility, afterload • Increased preload via RAA • Worsening ischaemia & Pulmonary consequences

  11. The Fallout • Pathophysiology • Tissue Hypoxia • Results in increased products of anaerobic metabolism including lactate, and a decrease in pH • Worsens myocardial performance • The Latest • Systemic inflammatory response • Cytokines, interleukins, inducible NO synthase • Consequences for genesis, treatment & outcome

  12. Assessing The Damage • Symptoms & Signs • Emergency - ‘Time is muscle’ (or Tissue) • Signs of inadequate tissue perfusion • CVS including elevated JVP, pulmonary oedema, extra heart sounds, murmur, arrhythmia • Echo - wall motion, papillary muscle, valvular function • Invasive monitoring

  13. Damage Control • Initial Management • General Supportive • Infarct • Shock

  14. Damage Control • Initial Management • General Supportive • Correct hypoxia / acidosis • Relieve pain • Correct electrolytes

  15. Damage Control • Initial Management • Infarct • Aspirin • Clopidogrel • Heparin • GPIIb/IIIa inhibitors • NSTEMI

  16. Damage Control • Initial Management • Infarct • Thrombolysis / PTCA / CABG / VR • Avoidance of agents with negative inotropic effects - beta blockers, calcium channel blockers

  17. Damage Control • Initial Management • Shock • Volume resuscitation, especially if cause is due to RV infarction • Guided by Sats, MAP, CO, PCWP - aim for lowest value to give highest CO. Often 18-25mmHg • Pulmonary oedema • Diuretics • Vasodilators

  18. Invasive monitoring • All modalities should be considered • Arterial line - almost universal • Central line - required for administration of inotropes • PA catheter / PiCCO • Refractory hypotension • Mechanical complications & cause • Vasopressor / Inotropic agents

  19. Putting The Squeeze On • Vasopressors & Inotropes • Vasopressors • Agents that produce vasoconstriction • Mostly sympathomimetics, catechol and non-catecholamines • Directly acting agents • Inotropes • Agents that increase myocardial contractility • Sympathomimetics • Phosphodiesterase inhibitors • Others

  20. Putting The Squeeze On • First Line • Dopamine • Noradrenaline • Second Line • Dobutamine • Milrinone

  21. Putting The Squeeze On • First Line • Dopamine • Naturally occuring sympathomimetic amine, with effects at α, β, and DA receptors • Low dose β effects predominate, high does α • Both vasoconstrictor and inotropic effects • Increases PCWP • Risk of arrhythmia (>NA latest NEJM) • Tachycardia, increased O2 demand

  22. Putting The Squeeze On • First Line • Noradrenaline • Potent naturally occurring sympathomimetic amine and neurotransmitter, with effects at α & β receptors • Predominant α effects • Tissue necrosis • Risk of arrhythmia • Adrenaline - substitute for Dopamine

  23. Putting The Squeeze On • First Line • Considerations • Vasopressors typically increase SVR, with limited direct effect on CO • Increased SVR may worsen CO - consider invasive monitoring

  24. Putting The Squeeze On • Second Line • Dobutamine • Synthetic catecholamine, predominantly β effects • Increases inotropy and chronotropy, often of benefit in cardiac failure • May worsen hypotension • Risk of arrhythmia • Can be combined with Dopamine

  25. Putting The Squeeze On • Second Line • Milrinone • Selective PDE III inhibitor inotropic agent • Increases CO via increased cAMP • Additionally has vascular vasodilating effects • Risk of hypotension and arrhythmia • No studies to demonstrate benefit

  26. Party Time • IABP & other VADs • Benefit of improving coronary perfusion and cardiac performance • Reduce myocardial ischaemia & cardiac work • Do not alter SVR

  27. Party Time • IABP • Description • Intravascular counterpulsation device used to augment cardiac function • Haemodynamic Effects • Displacement of blood into proximal aortic territory during diastole • Increases coronary & cerebral blood flow • Reduction in afterload 2o to ‘vacuum’ effect • Reduces cardiac work

  28. Party Time • IABP • Consequences • Improved myocardial O2 supply and reduced O2 demand • Improvement in end organ function, reduction in acidosis • In cardiogenic shock used as adjunct to definitive treatment. In isolation does not improve mortality

  29. Party Time • IABP • Uses/Indications • Cardiogenic shock • Including AMI & mechanical lesions eg MR • Support post PTCA • Weaning from CPB • Refractory unstable angina / High risk restenosis PTCA or thrombolysis

  30. Party Time • IABP • Contraindications • Absolute • Moderate & Severe Aortic Regurgitation • Dissecting Aortic Aneurysm • Relative • PVD • AAA

  31. Party Time • IABP • Complications • Vascular • Limb ischaemia • Vascular laceration • Major Haemorrhage • Non-Vascular • Embolization • Balloon migration & ischaemia cerebral, renal • Sepsis • Balloon rupture

  32. Party Time • IABP • Complications • Other • Haemolysis • Thrombocytopaenia • Peripheral neuropathy • Practical • Anticoagulation • Post CABG • AMI

  33. Party Time • IABP • Practical • Triggering • ECG • Pacing • Arterial pressure • Monitoring • Peak diastolic will be higher than systolic (augmented) • Continue to use MAP on IBP to guide ‘tropes’

  34. Party Time • IABP • Practical • Modes - 1:1, 1:2, 1:4 • Size does matter • Differing volume of balloon for height • Weaning • Stable haemodynamics typically after 24-48/24 • Reduce inflation ratio, off after ~ 2/24 at 1:4

  35. Finding Solutions • Definitive Treatment • Thrombolysis • Revascularization • CABG / VR

  36. Finding Solutions • Definitive Treatment • Thrombolysis • Evidence suggests benefit over placebo in cardiogenic shock, improved survival • Use in combination with IABP • PTCA and CABG superior • Consider in patients who are high risk, in areas without angiographic services

  37. Finding Solutions • Definitive Treatment • Revascularization • Mainstay of AMI induced cardiogenic shock • Early intervention preferable • Improvement in both infarct and remote myocardium • Response may be variable, and not immediately apparent

  38. Finding Solutions • Definitive Treatment • CABG / VR • Benefit demonstrated inlimited capacity in trials • Relatively low mortalityrate • Significant logisticalchallenges • Typically limited to thosewith mechanical causesof cardiogenic shock

  39. Going Back For Seconds • Why Treatment Works • Stunning • Hibernation

  40. Moving On • Outcomes • High mortality • Limited scope forrecovery

More Related